Key result
Infant poliovirus type 1 seroprevalence increases by ~14 percentage points, driven by oral vaccine doses.
Why the study?
Seroprevalence data before and after interruption of poliovirus transmission in Kano State, Nigeria, were needed to assess immunity levels and impact of immunization programs.
Cross-Sectional (n=965)
No
Answers are grounded in this paper and cite their sources.
INTRODUCTION: In September 2015, Nigeria was removed from the list of polio-endemic countries after more than 12months had passed since the detection of last wild poliovirus case in the country on 24 July 2014. We are presenting here a report of two polio seroprevalence surveys conducted in September 2013 and October 2014, respectively, in the Kano state of northern Nigeria. METHODS: Health facility based seroprevalence surveys were undertaken at Murtala Mohammad Specialist Hospital, Kano. Parents or guardians of children aged 6-9months, 36-47months, 5-9years and 10-14years in 2013 and 6-9months and 19-22months (corresponding to 6-9months range at the time of 2013 survey) in 2014 presenting to the outpatient department, were approached for participation, screened for eligibility and asked to provide informed consent. A questionnaire was administered and a blood sample collected for polio neutralization assay. RESULTS: Among subjects aged 6-9months in the 2013 survey, seroprevalence was 58% (95% confidence interval [CI] 51-66%) to poliovirus type 1, 42% (95% CI 34-50%) to poliovirus type 2, and 52% (95% CI 44-60%) to poliovirus type 3. Among children 36-47months and older, seroprevalence was 85% or higher for all three serotypes. In 2014, seroprevalence in 6-9month infants was 72% (95% CI 65-79%) for type 1, 59% (95% CI 52-66%) for type 2, and 65% (95% CI 57-72%) for type 3 and in 19-22months, 80% (95% CI 74-85%), 57% (49-63%) and 78% (71-83%) respectively. Seroprevalence was positively associated with history of increasing oral poliovirus vaccine doses. CONCLUSIONS: There was significant improvement in seroprevalence in 2014 over the 2013 levels indicating a positive impact of recent programmatic interventions. However the continued low seroprevalence in 6-9month age is a concern and calls for improved immunization efforts to sustain the polio-free Nigeria.
No takes yet. Share an insight, caveat, or question.
Iliyasu et al. (2016) conducted a cross-sectional in Poliovirus immunity (n=965). 2014 time period and OPV vaccination vs. 2013 time period was evaluated on Poliovirus type 1 seroprevalence in 6-9 month old infants (p=0.009). Poliovirus type 1 seroprevalence in 6-9 month old infants increased significantly from 58% in 2013 to 72% in 2014, with seropositivity strongly associated with the number of oral poliovirus vaccine doses received.
Synapse has enriched 10 related papers. Consider them for comparative context: